 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Doxil- Doxil
- Ortho Biotech Brand of Doxorubicin Hydrochloride
Doxorubicin NC- Doxorubicin NC
- Neocorp Brand of Doxorubicin Hydrochloride
Doxotec- Doxotec
- Columbia Brand of Doxorubicin Hydrochloride
Farmiblastina- Farmiblastina
- Kenfarma Brand of Doxorubicin Hydrochloride
Myocet- Myocet
- Elan Brand of Doxorubicin Hydrochloride
Onkodox- Onkodox
- Onkoworks Brand of Doxorubicin Hydrochloride
Ribodoxo- Ribodoxo
- ribosepharm Brand of Doxorubicin Hydrochloride
Rubex- Rubex
- Bristol-Myers Squibb Brand of Doxorubicin Hydrochloride
Adriblastin- Adriblastin
- Pfizer Brand of Doxorubicin Hydrochloride
- Adriblastina
- Adriblastine
- Adriablastin
- Adriablastine
Adriamycin- Adriamycin
- Bedford Brand of Doxorubicin Hydrochloride
Adrimedac- Adrimedac
- medac Brand of Doxorubicin Hydrochloride
Caelyx- Caelyx
- Schering Brand of Doxorubicin Hydrochloride
- Schering-Plough Brand of Doxorubicin Hydrochloride
- Essex Brand of Doxorubicin Hydrochloride
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
- cell pharm Brand of Doxorubicin Hydrochloride
Doxolem- Doxolem
- Lemery Brand of Doxorubicin Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1981 | 0 | 2 | 2 | | 1982 | 1 | 5 | 6 | | 1983 | 0 | 4 | 4 | | 1984 | 0 | 5 | 5 | | 1985 | 2 | 2 | 4 | | 1986 | 0 | 2 | 2 | | 1987 | 1 | 2 | 3 | | 1988 | 1 | 4 | 5 | | 1989 | 3 | 2 | 5 | | 1990 | 1 | 2 | 3 | | 1991 | 2 | 3 | 5 | | 1992 | 0 | 3 | 3 | | 1993 | 0 | 1 | 1 | | 1994 | 2 | 2 | 4 | | 1995 | 2 | 2 | 4 | | 1996 | 0 | 3 | 3 | | 1997 | 2 | 2 | 4 | | 1998 | 0 | 6 | 6 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 3 | 4 | | 2001 | 5 | 5 | 10 | | 2002 | 1 | 4 | 5 | | 2003 | 0 | 3 | 3 | | 2004 | 1 | 8 | 9 | | 2005 | 0 | 8 | 8 | | 2006 | 2 | 4 | 6 | | 2007 | 2 | 8 | 10 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 6 | 6 | | 2010 | 6 | 5 | 11 | | 2011 | 4 | 5 | 9 | | 2012 | 1 | 7 | 8 | | 2013 | 3 | 7 | 10 | | 2014 | 3 | 3 | 6 | | 2015 | 3 | 5 | 8 | | 2016 | 1 | 6 | 7 | | 2017 | 1 | 4 | 5 | | 2018 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124.
-
Knowles DA, Burrows CK, Blischak JD, Patterson KM, Serie DJ, Norton N, Ober C, Pritchard JK, Gilad Y. Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes. Elife. 2018 05 08; 7.
-
Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, Attygalle AD, Zerizer I, Sharma B, Chua S, Begum R, Chau I, Johnson P, Ardeshna KM, Hawkes EA, Macheta MP, Collins GP, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol. 2018 May; 5(5):e190-e200.
-
Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659.
-
Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer. 2018 01 01; 124(1):136-144.
-
Hatanaka M, Anderson-Baucum E, Lakhter A, Kono T, Maier B, Tersey SA, Tanizawa Y, Evans-Molina C, Mirmira RG, Sims EK. Chronic high fat feeding restricts islet mRNA translation initiation independently of ER stress via DNA damage and p53 activation. Sci Rep. 2017 06 19; 7(1):3758.
-
Luczak M, Kubicki T, Rzetelska Z, Szczepaniak T, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Jakubowiak A, Komarnicki M, Dytfeld D. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Pol Arch Intern Med. 2017 06 30; 127(6):392-400.
-
Pillai VB, Kanwal A, Fang YH, Sharp WW, Samant S, Arbiser J, Gupta MP. Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget. 2017 May 23; 8(21):34082-34098.
-
Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017 08; 146(2):247-253.
-
Agiro A, Ma Q, Acheson AK, Wu SJ, Patt DA, Barron JJ, Malin JL, Rosenberg A, Schilsky RL, Lyman GH. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. J Clin Oncol. 2016 11 10; 34(32):3872-3879.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|